rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
The Impact of Oral and Nasal Enteral Nutrition Feeding Quantity in Stroke Patients
Status: Not yet recruiting

The goal of this clinical trial is to compare the differences in feeding amount and nutritional status between ischemic stroke patients using Intermittent Oro-esophageal Tube and Nasogastric Tube. Patients will be randomly divided into an observation group and a control group, all receiving routine rehabilitation treatment. On this basis, the observation group will use Intermittent Oro esophageal Tube for enteral nutrition support, while the control group will use Nasogastric Tube. Researchers will compare changes in daily intake and nutritional status of two groups of patients before and after the study to see if Intermittent Oro-esophageal Tube can improve the feeding amount and nutritional status between ischemic stroke patients compared to Nasogastric Tube

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age>18 years. Meeting the diagnostic criteria for ischemic stroke . Dysphagia confirmed by Videofluoroscopic Swallowing Study. Clear consciousness. No history of prior stroke. Stable vital signs.  Exclusion Criteria:  Dysphagia that might be caused by other diseases that might cause dysphagia, such as head and neck tumors, traumatic brain injury, myasthenia gravis, etc. Complicated with severe liver and kidney failure, tumors, or hematological disorders. Simultaneously in need to undergo other therapy that might affect the outcomes of this study. Pregnant or nursing females. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Impact of Neck and Facial Exercises on Swallowing Function in Elderly Individuals
Status: Not yet recruiting

The goal of this clinical trial is to explore the impact of systematic simple swallowing training on swallowing function and quality of life in community-dwelling elderly individuals (≥60 year old) with swallowing disorders. It primarily aims to address two key aspects: 1) the prevalence of dysphagia among community-dwelling elderly individuals, and 2) the effects of systematic simple swallowing training on swallowing function and quality of life in community-dwelling elderly individuals with swallowing disorders. All participants are required to undergo a continuous three-week (21 days) systematic simple swallowing training, with weekends off and training conducted only on weekdays. The training will be conducted two sessions per day, lasting 15-30 minutes each.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age over 60 years old. No hospitalization within the past six months. With clear consciousness and able to cooperate with questionnaires and training. The elderly people who voluntarily participate and agree to adhere until the end of the study.  Exclusion Criteria:  Complicated with severe liver and kidney failure, tumors, or hematological disorders. Physical disability. Difficulty in mobility. - HealthyVolunteers: No - Gender: All - MinimumAge: 60 Years - StdAgeList: Adult, Older Adult
Retrospective Analysis of Speech Performance Using the HiRes Ultra and HiRes Ultra 3D Cochlear Implant
Status: Recruiting

This is a retrospective study designed to collect speech perception results for HiRes Ultra CI and HiRes Ultra 3D CI users as measured in the clinical routine and to confirm the performance of these devices.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Unilateral or bilateral HiRes Ultra CI or HiRes Ultra 3D CI users including  Ultra Version V2 newly implanted on this side (Group 1) Ultra Version V2 users implanted following an Ultra Version V1 device failure in the same ear (Group 2) Informed consent signed  Exclusion Criteria:  no exclusion criteria - HealthyVolunteers: No - Gender: All - StdAgeList: Child, Adult, Older Adult - StudyPopulation: The studied population consists of all CI users implanted with a HiRes Ultra Version V2 or HiRes Ultra 3D Version V2 CI at the Medical University of Hannover in Germany (MHH). - SamplingMethod: Non-Probability Sample
Retrospective Analysis of Long-term Speech Performance in Cochlear Implant Recipients Using Electro-acoustic Stimulation
Status: Recruiting

This is a retrospective study designed to collect long-term speech perception results for cochlear implants recipients using electro-acoustic-stimulation as measured in the clinical routine and to confirm the performance of sound processors associated with acoustic earhooks.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Being implanted with HiRes Ultra or HiRes Ultra 3D SlimJ Being a user of the "acoustic earhook" system Having provided informed consent regarding use of his/her data for research.  Exclusion Criteria:  no exclusion criteria - HealthyVolunteers: No - Gender: All - StdAgeList: Child, Adult, Older Adult - StudyPopulation: The studied population consists of all CI users implanted with a HiRes Ultra or HiRes Ultra 3D SlimJ between January 2017 and August 2022 and using an acoustic earhook at the Medical University of Hannover in Germany (MHH) - SamplingMethod: Non-Probability Sample
Multimodal, Task-Aware Movement Assessment and Control Using Functional Electrical Stimulation
Status: Recruiting

The study aims to investigate the relationship between post-stroke adults' movement patterns and disability levels. Utilizing the functional electrical stimulation (FES) system for individualized dorsiflexor and plantar flexor assistance during gait cycles. The investigators will analyze the cycles with and without the FES system. Initially, the context-aware motion assessment and neuroprosthetic control in a clinic will transition to in-home settings as the study progresses, broadening its application for safe and effective use at home.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age >= 18 years Capacity to consent Post-stroke community-dwelling adults Ability to follow 3-step commands  Exclusion Criteria:  Undomiciled Active substance use disorder Active psychosis Domestic violence or neglect Inability to communicate with investigators Other comorbidities that prevent full participation in the research - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Twenty post-stroke community-dwelling adults will participate in a single in-laboratory and in-home visit, performing 5x sit-to-stand (5XSST), 5x Comfortable and 3x Fast walking speed at a 5M distance, and 5x modified Timed Up and Go (TUG). The tests will be performed twice: once with and without the task aware-neuroprosthesis. - SamplingMethod: Non-Probability Sample
Impact VR: An Emotion Recognition and Regulation Training Program for Youth With CD
Status: Recruiting

Conduct disorder (CD) is one of the most prevalent childhood psychiatric disorders. Unfortunately, there are limited treatments available for CD. The present study aims to test an innovative virtual reality intervention called Impact VR for symptom reduction in a sample of 60 youth with CD.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Aged 10-17 years old Identified through the TriNetX database as having a conduct disorder diagnosis English speaking  Exclusion Criteria:  Youth aged <10 years and >18 years old Non-English speaking Youth of caregivers younger than 18 years old. - HealthyVolunteers: No - Gender: All - MinimumAge: 10 Years - MaximumAge: 17 Years - StdAgeList: Child
Postoperative Quality of Recovery After Combined Lumbar Plexus-Sciatic Nerve Block (LPB-SNB)
Status: Not yet recruiting

The goal of this clinical trial is to evaluate the efficacy of lumbar plexus-sciatic nerve block (LPB-SNB) by comparing the postoperative quality of recovery as assessed by the Quality of Recovery-40 (QoR-40) questionnaire, in patients who received a combination of LPB-SNB versus patients who received the traditional intravenous opioid, after lower extremity orthopaedic surgeries with spinal anaesthesia.

The main questions it aims to answer are:

Will there be a significant difference in QoR-40 scores between both groups?
Will the combined LPB-SNB significantly reduces opioid consumption within the first 24 hours?
Will the combined LPB-SNB significantly increases postoperative duration of analgesia?

Participants will:

Receive a coded sealed opaque envelope containing their randomly allocated intervention group; first group receives a combination of lumbar plexus-sciatic nerve block, while the second group receives no block at all. This information would not be disclosed to the participants.
Receive an explanation on how to use the patient controlled analgesia (PCA) to deliver intravenous opioid, and instructions on filling in the QoR-40 questionnaire.

Researchers will then compare the results between both groups to see if the combined lumbar plexus-sciatic nerve block successfully provides adequate analgesia and enhance postoperative quality of recovery after lower extremity orthopaedic surgeries.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients undergoing lower extremity orthopaedic surgery with spinal anaesthesia Patients aged between 18-65 years Patients with American Society of Anesthesiologists (ASA) physical status classification of I-III Patients with a body mass index (BMI) between 18-30 kg/m2  Exclusion Criteria:  Patients with a history of allergy towards the local anaesthetic agents used Patients with contraindication to regional anaesthesia based on the American Society for Regional Anesthesia guidelines Patients with pre-existing mental or psychological disorders - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
PRecisiOn Microbiome Directed ExtensiOn of Anti-TNFα Crohn's Disease ThErapy in Children: The PROMOTE Trial
Status: Not yet recruiting

To determine whether a specific food-origin plant-derived resistant starch (RS) optimized for the individual will increase the abundance of known butyrate producing microbes.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age between 8.0 to 16.9 years of age. Capable of giving informed consent, or if appropriate, have an acceptable representative capable of giving consent on the participant's behalf. Established Crohn's Disease (CD) diagnosis with the site of disease involving at least the terminal ileum or ascending colon. CD is in clinical remission or with mild stable disease activity (weighted Pediatric Crohn's Disease Activity Index of 0 to 39.5). Receiving infliximab or adalimumab anti-TNFa monoclonal antibody medication for treatment of CD. No changes in medical treatment for the previous month and without anticipated changes for the next month. Ability and willingness to comply with study procedures (e.g., stool collection) for the entire length of the study.  Exclusion Criteria:  Allergy to RS or excipients. Co-existing diagnosis with diabetes mellitus type 1. Treatment with another investigational drug or intervention throughout the study. Current illicit drug or alcohol dependence. Inability or unwillingness of an individual or legal guardian to give written informed consent. Other conditions requiring immunomodulating or biological medications. Pregnancy. Participant's microbiota does not increase butyrate production utilizing any RS from the assembled panel as measured through the RapidAIM ex vivo assay. - HealthyVolunteers: No - Gender: All - MinimumAge: 8 Years - MaximumAge: 16 Years - StdAgeList: Child
Dalpiciclib in HR+/HER2- ABC
Status: Not yet recruiting

To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Histologically confirmed advanced breast cancer Hormone receptor-positive and human epidermal growth factor receptor 2-negative ECOG 0-1  Exclusion Criteria:  Pregnant or breastfeeding History of immunodeficiency - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer - SamplingMethod: Non-Probability Sample
MRD Response-adapted Allo-HSCT for Adverse-risk AML
Status: Not yet recruiting

This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Newly diagnosed AML; Categorized into adverse-risk group according to ELN 2022 criteria; 16-65 years of age at the time of diagnosis; achieving CR after 1 or 2 courses of induction chemotherapies;  4) ECOG PS score of 0 to 1 5) It needs consent from the patients or/and legal guardian, and signature on the Informed Consent.  Exclusion Criteria:  Newly diagnosed AML, but categorized into favorite- or intermediate-risk group according to ELN 2022 criteria; < 16 years, or older than 65 years at the time of diagnosis; Achieving CR after 3 or more courses of induction chemotherapies, or could not achieve CR after induction chemotherapies; ECOG PS score of 2 or more; Patients with other comorbidities or mental diseases that influence the life safety and compliance of patients as well as affect informed consent, enrollment in the research, follow-up visit or result interpretation. - HealthyVolunteers: No - Gender: All - MinimumAge: 16 Years - MaximumAge: 65 Years - StdAgeList: Child, Adult, Older Adult
Combination of Hypothermia and Thrombectomy in Acute Stroke
Status: Not yet recruiting

The goal of this clinical trial is to test the combination of hypothermia and endovascular treatment in acute stroke patients with large vessel occlusion.

The main question it aims to answer is: does an additional cooling to 35°C result in a benefit on clinical outcome ? Participants receive immediate cooling using a noninvasive transnasal cooling technique (RhonoChill) and are maintained at 35°C for 6 hours after reopening of the vessel using surface cooling, and then slowly rewarmed.

Researchers will compare the intervention group (hypothermia and endovascular treatment and best medical treatment including iv thrombolysis) and control group (only endovascular treatment and best medical treatment including iv thrombolysis) to see if additional hypothermia leads to a better outcome after 3 months without relevant complications.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Pre-stroke modified Rankin Scale (mRS) 0-2 [7-point scale rating from 0 (no symptoms) to 6 (dead)] Acute ischemic stroke with NIHSS >5 Intracranial occlusion of the M1 or M2 segment of the middle cerebral artery (MCA) or internal carotid artery (ICA) or tandem occlusion on CT-angiography or MR-angiography with indication for endovascular treatment:  Time window 0-24h:  Last seen normal to groin puncture < 6h: native CT or MRI-DWI with ASPECTS >5  Last seen normal to groin puncture 6-24h or unknown time window: significant mismatch imaging according to the eligibility criteria of the DEFUSE-3 trial  Infarct core <70ml (DWI oder CBF<30%) Penumbra > 15ml (Tmax >6sec) Ratio penumbra/core >1.8 with or without iv thrombolysis with rtPA  Exclusion Criteria:  Patients with an intranasal obstruction that prevents complete insertion of the nasal cannula should not be treated with the RhinoChill system. Known severe hemorrhagic diathesis (International Normalized Ratio (INR) >3.0, partial thromboplastin time (PTT) > 70s, platelet count < 50.000/μl) Brain trauma or neurovascular surgery/intervention <3 months Severe infection Pregnant women or women of childbearing potential (women of childbearing potential with negative pregnancy test may be included) Known cerebral vasculitis Proof of bleeding in cerebral CT or MRI (cerebral microbleeds in MRI [hypertensive or in the context of cerebral amyloid angiopathy] is permitted). Known life expectancy < 6 months - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Learning Through Play Plus for Psychosis
Status: Not yet recruiting

Evidence reports that parents with schizophrenia are particularly vulnerable to parenting difficulties and also experience problems in sensitively interacting with their children. This may cause insecure attachment in infants of mothers with psychosis. Children of parents with schizophrenia have poor developmental and clinical outcomes. However, there is no published trial, to the best of our knowledge, for children of parents with schizophrenia. Learning through Play (LTP) is a potentially low cost intervention to improve maternal mental health and child outcomes by promoting health child development. The proposed study will integrate LTP with existing culturally appropriate Cognitive Behaviour Theray (CBT) for psychosis (CaCBT-p) and test its feasibility and acceptability for parents with schizophrenia.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Diagnostic and Statistical Manual-V (DSM-V) diagnosed first episode psychosis, schizophrenia, schizoaffective disorder, psychosis not otherwise specified or schizophreniform disorder. Parents (Mother or Father), age 18 year and above Parents (Mother or Father) having a child from birth to 36 months Parents (Mother or Father) living within the catchment area of recruitment site. Competent and willing to give informed consent Parents (Mother or Father) are stable on medication for at least 3 months prior to the intervention.  Exclusion Criteria:  Violation of any inclusion criteria Failure to perform screening or baseline examinations. Patients who will meet the criteria for a DSM-V diagnosis of alcohol or substance abuse (other than for nicotine) within the last month or the criteria for DSM-V alcohol or substance dependence (other than for nicotine) within the last 6 months Temporary resident unlikely to be available for follow up. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Block and Erector Comparative Study Between Costotransverse Spinae Plane Block in Patients Undergoing Thoracotomy
Status: Not yet recruiting

A thoracotomy requires a very painful incision, involving multiple muscle layers, rib resection and continuous motion as the patient breathes. Treatment of acute post thoracotomy pain is particularly important not only to keep the patient comfortable but also to minimize pulmonary complications

Though epidural analgesia was once considered as the gold standard for post-thoracotomy pain management, it is not recommended for pain control after thoracotomy surgery because it is associated with high potential risks of dural puncture, nerve lesions, epidural hematoma and hypotension(4). Thoracic paravertebral block (TPVB) and intercostal nerve block are well described and recognized techniques for postoperative analgesia following thoracic surgeries, such as thoracotomy and mastectomy

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  • Age from 18 to 75 years old.  Both sexes. American Society of Anesthesiologists (ASA) physical status I-II-III. Patient undergoing unilateral thoracotomy surgery.  Exclusion Criteria:  • BMI more than 30 kg/m2.  Patients who are taking analgesics for chronic illness or have a history of substance abuse. Patients who are unable to describe their postoperative pain (e.g., language barrier or neuropsychiatric disorder). Patients with a history of coagulopathy. Severe heart diseases. Hepatic or renal insufficiency. Infection at the site of infiltration - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult
The Evaluation and Comparison of BCR-ABL p210 mRNA Transcripts (%IS Unit) Results Between Dr. PCR™ BCR-ABL1 Major IS Detection Kit (Optolane) and QXDx™ BCR-ABL %IS Kit (Bio-Rad) in Chronic Myeloid Leukemia Patients
Status: Recruiting

Today, there are many commercial kits for detecting BCR-ABL fusion transcripts. The QXDx™ BCR-ABL %IS kit (Bio-Rad, Hercules, CA, USA) is the first ddPCR-based in vitro diagnostics (IVD) product with the US Food and Drug Administration clearance and European Conformity (CE) mark which launched in 2017. Dr. PCR™ BCR-ABL1 Major IS Detection Kit (Optolane, South Korea) is one of CE-IVD commercial kits based on digital RT-PCR. Both commercial kits are digital PCR-based, also evaluated their correlation, pros and cons in order for users to select a reagents kit that are appropriate for themselves.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Leftover RNA samples from CML patients were recruited from the Hematology Laboratory Division of Hematology Department of Medicine Faculty of Medicine, Siriraj Hospital Mahidol University, after TKI treatment and regular follow-ups or newly diagnosed. All samples were successively tested by QXDx BCR-ABL %IS Kit (Bio-Rad) which used Droplet Digital PCR (ddPCR) technique.  Exclusion Criteria:  In adequate or poor-quality specimen - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The patients 18 years and older who were newly diagnosis and known to have CML - SamplingMethod: Probability Sample
A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial
Status: Recruiting

The goal of this clinical trial is to learn about a novel application of lidocaine injection in male patients who needs rigid cycstoscopy test. The main question it aims to answer is:Does New Application of Lidocaine Liquid Provide Pain Relief for Patients During Cystoscopy? Before the cycstoscopy,Participants will be randomly divided into three different anesthesia mode groups,namely are Group A (intraurethral lidocaine gel alone), Group B (intraurethral lidocaine gel + lidocaine 2% injection), and Group C (intraurethral lidocaine gel + liquid paraffinl).Patients only need to prepare and cooperate according to routine surgical operations，which is group B or group C.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male patients under the age of 50 referred for postoperative cystoscopy for bladder cancer  Exclusion Criteria:  - 1. Other evident causes contributing to lower urinary tract symptoms, such as obvious glandular cystitis and severe urinary tract infections.  2. Excessive prostatic hyperplasia. 3. Urethral stricture. 4. A history of prior urethral surgeries. 5. Uncontrolled hypertension, cardiac conditions, and chronic obstructive pulmonary disease. - HealthyVolunteers: No - Gender: Male - MaximumAge: 50 Years - StdAgeList: Child, Adult
Feasibility of Targeted Bronchial Washing Fluid for Molecular Testing With Next Generation Sequencing in Patients Suspicious of Early-stage Lung Cancer
Status: Not yet recruiting

This is a single center, clinical trial evaluating the relevance of intratumoral washing for detection of generic alteration with Next Generation Sequencing.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age ≥ 20 years Obtained written informed consent Subjects suspected with resectable lung cancer and planning to undergo bronchoscopy Subjects with no contraindication to brochoscopy Subjects planning to undergo surgery for suspected lung cancer and opting for tissue or liquid biopsy for genetic alteration using Next Generation Sequencing  Exclusion Criteria:  Patients who withdraw informed consent Patients who are unable to undergo liquid biopsy (plasma) and tissue biopsy for genetic alteration with Next Generation Sequencing based on the investigator's judgement - HealthyVolunteers: No - Gender: All - MinimumAge: 20 Years - StdAgeList: Adult, Older Adult